Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates.
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
15
01
2020
pubmed:
8
4
2020
medline:
22
7
2020
entrez:
8
4
2020
Statut:
ppublish
Résumé
Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear. In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively). IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.
Sections du résumé
BACKGROUND
Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear.
METHODS
In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY:
RESULTS
In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively).
CONCLUSIONS
IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.
Identifiants
pubmed: 32253263
pii: peds.2019-2689
doi: 10.1542/peds.2019-2689
pmc: PMC7193977
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA187707
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Références
Acad Pediatr. 2017 Apr;17(3):330-338
pubmed: 27913163
Health Aff (Millwood). 2009 Jan-Feb;28(1):75-85
pubmed: 19124857
Acad Pediatr. 2018 Mar;18(2S):S14-S16
pubmed: 29502629
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
Pediatrics. 2003 Nov;112(5):1076-82
pubmed: 14595049
Pediatrics. 2016 Sep;138(3):
pubmed: 27581853
Vaccine. 2018 Aug 6;36(32 Pt B):4904-4909
pubmed: 30037480
Hum Vaccin Immunother. 2017 Mar 4;13(3):680-686
pubmed: 27763818
J Adolesc Health. 2015 May;56(5 Suppl):S40-6
pubmed: 25863554
Acad Pediatr. 2018 Mar;18(2S):S3-S10
pubmed: 29502635
Acad Pediatr. 2016 Jan-Feb;16(1):50-6
pubmed: 26525988
Acad Pediatr. 2012 Jan-Feb;12(1):26-35
pubmed: 21900066
CA Cancer J Clin. 2013 Jan;63(1):57-81
pubmed: 23258613
JAMA Pediatr. 2015 Apr;169(4):365-73
pubmed: 25706340
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
J Adolesc Health. 2015 May;56(5 Suppl):S17-20
pubmed: 25863549
Acad Pediatr. 2018 Nov - Dec;18(8):873-881
pubmed: 30031132
Acad Pediatr. 2011 Jan-Feb;11(1):44-9
pubmed: 21272823
Hum Vaccin Immunother. 2018 Jul 3;14(7):1626-1635
pubmed: 29359986
J Clin Epidemiol. 2009 May;62(5):464-75
pubmed: 19348971
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Pediatr Infect Dis J. 2005 Jun;24(6 Suppl):S134-40
pubmed: 15931141
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924
pubmed: 30138307
J Adolesc Health. 2015 Jan;56(1):85-90
pubmed: 25438965
MMWR Morb Mortal Wkly Rep. 2012 Apr 20;61:258-61
pubmed: 22513527
Am J Public Health. 2013 Jun;103(6):1116-23
pubmed: 23237154
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003941
pubmed: 16034918
Acad Pediatr. 2018 Mar;18(2S):S1-S2
pubmed: 29502626
Acad Pediatr. 2013 May-Jun;13(3):204-13
pubmed: 23510607
JAMA. 2000 Oct 11;284(14):1820-7
pubmed: 11025835
Pharmacoeconomics. 2005;23(11):1107-22
pubmed: 16277547
Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941
pubmed: 29342498
Pediatrics. 2003 Oct;112(4):958-63
pubmed: 14523192
Health Educ Q. 1984 Spring;11(1):1-47
pubmed: 6392204
Acad Pediatr. 2014 Jan-Feb;14(1):62-70
pubmed: 24369870
Acad Pediatr. 2018 Mar;18(2S):S72-S78
pubmed: 29502641
Hum Vaccin Immunother. 2019;15(7-8):1639-1640
pubmed: 30188782
Acad Pediatr. 2018 Mar;18(2S):S23-S27
pubmed: 29502633